Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy
- 1 November 1995
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 92 (9), 2373-2380
- https://doi.org/10.1161/01.cir.92.9.2373
Abstract
No abstract availableThis publication has 56 references indexed in Scilit:
- Bypass Angioplasty Revascularization Investigation: Patient Screening, Selection, and RecruitmentThe American Journal of Cardiology, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Vitronectin and its receptorsCurrent Opinion in Cell Biology, 1993
- Intravenous administration of monoclonal antibody to the platelet GP IIb/IIIa receptor to treat abrupt closure during coronary angioplastyThe American Journal of Cardiology, 1992
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992
- Platelets and Thrombolytic TherapyNew England Journal of Medicine, 1990
- Clinical Implications of Prostaglandin and Thromboxane A2FormationNew England Journal of Medicine, 1988
- Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.JCI Insight, 1988
- Platelet Membrane Glycoprotein IIb/IIIa: Member of a Family of Arg-Gly-Asp—Specific Adhesion ReceptorsScience, 1986
- Exposure of platelet fibrinogen receptors by ADP and epinephrine.JCI Insight, 1979